Omnicom Group Inc. vs Revvity Inc — how do they compare? Omnicom Group Inc. trades at $76.39 (market cap $20.97B), while Revvity Inc trades at $154.66 (market cap $16.98B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays the higher dividend (4.19%). Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and Revvity Inc for 12 Days on average.
| OMC | RVTY | |
|---|---|---|
Market Cap | $20.97B | $16.98B |
Volume | 2,092,899 | 1,456,900 |
Sector | Media | Health |
52-Week High | $88.94 | $157.36 |
52-Week Low | $67.27 | $82.26 |
Typical Hold Time | 63 Days | 12 Days |
Enterprise Value | $29.05B | $19.30B |
Dividend Yield | 4.19% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $74.87, down 0.31% on the day, with a bearish technical outlook. The stock shows mixed fundamentals with strong revenue growth to $17.27B in 2025 but negative net income of -$54.5M. Recent business developments include significant new billings of $3.3B in H1 2026 and leadership recognition in Gartner reports. Analyst consensus is mixed with 32% buy ratings but a $100.50 price target suggesting 34% upside potential.
OMC presents a value opportunity with attractive valuation metrics (P/S 0.86) and dividend yield, though recent earnings misses and high P/E ratio of 206.62 raise concerns. Key risks include advertising market volatility and debt levels, while catalysts include AI integration and post-merger synergies from the Interpublic acquisition.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →